MALDI protein profiling has identified several important challenges in omics-based biomarker research. First, research into the analytical performance of a novel omics-platform of potential diagnostic impact must be carried out in a critical manner and according to common guidelines. Evaluation studies should be performed at an early time and preferably before massive advancement into explorative biomarker research. In particular, MALDI profiling underscores the need for an adequate understanding of the causal relationship between molecular abundance and the quantitative measure in multivariate biomarker research. Secondly, MALDI profiling has raised awareness of the significant risk of false-discovery in biomarker research due to several confounding factors, including sample processing and unspecific host-response to disease. Here, the experience from MALDI profiling supports that a central challenge in unbiased molecular profiling is to pinpoint the aberrations of clinical interest among potentially massive unspecific changes that can accompany disease. The lessons from the first decade of MALDI protein profiling are relevant for future efforts in advancing omics-based biomarker research beyond the laboratory setting and into clinical verification.
|Tidsskrift||Journal of Proteomics|
|Status||Udgivet - 16 maj 2011|